TSX:EPRX • CA29842P1053
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for EUPRAXIA PHARMACEUTICALS INC (EPRX.CA).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2022-11-08 | Canaccord Capital | Downgrade | Buy |
| 2022-11-01 | Raymond James Capital | Upgrade | Outperform |
| 2022-06-09 | Raymond James Capital | Initiate | Outperform |
| 2022-04-21 | Canaccord Capital | Downgrade | Buy |
| 2022-04-01 | Raymond James Capital | Initiate | Outperform |
| 2021-11-12 | RaymondJamesFinancial | Downgrade | Outperform |
| 2021-08-18 | Canaccord Genuity | Downgrade | Buy |
| 2021-08-17 | Raymond James Financial | Initiate | Outperform |
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A -72.57% | N/A 198.68% | N/A 311.38% | N/A 81.67% | N/A 52.55% | N/A 37.56% | ||||||||||
| EBITDA YoY % growth | -4.64M | -11.75M -153.23% | -5.99M 49.02% | -2.27M 62.10% | -18.12M -698.24% | -22.77M -25.66% | -27.33M -20.03% | -25.32M 7.36% | -36.598M -44.54% | N/A -2.34% | N/A -5.00% | N/A 37.88% | N/A 128.85% | N/A 947.54% | N/A 89.98% | N/A 61.82% | N/A 38.68% | |
| EBIT YoY % growth | -4.73M | -11.88M -151.16% | -6.19M 47.90% | -2.39M 61.39% | -18.23M -662.76% | -22.96M -25.95% | -27.443M -19.53% | -25.434M 7.32% | -36.836M -44.83% | N/A -55.59% | N/A 56.47% | N/A -231.61% | N/A 48.85% | N/A 237.87% | N/A 162.31% | N/A 70.78% | N/A 44.90% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A 34.44% | -1.22 -1.36% | -1.03 15.74% | -1.44 -39.98% | N/A 42.92% | N/A 48.29% | N/A -55.16% | N/A 11.17% | N/A 196.81% | N/A 186.41% | N/A 77.05% | N/A 24.42% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.28 7.18% | -0.22 37.67% | -0.19 26.03% | -0.19 62.44% |
| Revenue Q2Q % growth | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -12.013M -78.95% | -9.792M -23.79% | -10.098M -54.92% | -10.302M 34.36% |
All data in USD
9 analysts have analysed EPRX.CA and the average price target is 14.96 CAD. This implies a price increase of 52.85% is expected in the next year compared to the current price of 9.79.
The consensus EPS estimate for the next earnings of EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) is -0.28 CAD and the consensus revenue estimate is 0 CAD.
The consensus rating for EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) is 82.2222 / 100 . This indicates that analysts generally have a positive outlook on the stock.